Prestige Consumer Healthcare Inc.

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, MCK has a market cap of 88.9B. Regarding current trading prices, PBH is priced at $74.65, while MCK trades at $712.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas MCK's P/E ratio is 27.71. In terms of profitability, PBH's ROE is +0.12%, compared to MCK's ROE of -1.33%. Regarding short-term risk, PBH is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check MCK's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, COR has a market cap of 56.2B. Regarding current trading prices, PBH is priced at $74.65, while COR trades at $289.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas COR's P/E ratio is 33.50. In terms of profitability, PBH's ROE is +0.12%, compared to COR's ROE of +2.41%. Regarding short-term risk, PBH is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check COR's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, CAH has a market cap of 37.6B. Regarding current trading prices, PBH is priced at $74.65, while CAH trades at $157.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas CAH's P/E ratio is 24.59. In terms of profitability, PBH's ROE is +0.12%, compared to CAH's ROE of -0.50%. Regarding short-term risk, PBH is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CAH's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, PBH is priced at $74.65, while ABC trades at $179.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas ABC's P/E ratio is 21.92. In terms of profitability, PBH's ROE is +0.12%, compared to ABC's ROE of +2.52%. Regarding short-term risk, PBH is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check ABC's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, HSIC has a market cap of 8.5B. Regarding current trading prices, PBH is priced at $74.65, while HSIC trades at $70.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas HSIC's P/E ratio is 21.82. In terms of profitability, PBH's ROE is +0.12%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, PBH is more volatile compared to HSIC. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check HSIC's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, PBH is priced at $74.65, while PDCO trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas PDCO's P/E ratio is 20.48. In terms of profitability, PBH's ROE is +0.12%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, PBH is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check PDCO's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, GRDN has a market cap of 1.3B. Regarding current trading prices, PBH is priced at $74.65, while GRDN trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas GRDN's P/E ratio is -12.79. In terms of profitability, PBH's ROE is +0.12%, compared to GRDN's ROE of -0.74%. Regarding short-term risk, PBH is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check GRDN's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, OMI has a market cap of 571.2M. Regarding current trading prices, PBH is priced at $74.65, while OMI trades at $7.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas OMI's P/E ratio is -1.57. In terms of profitability, PBH's ROE is +0.12%, compared to OMI's ROE of -0.51%. Regarding short-term risk, PBH is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check OMI's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, ZYXI has a market cap of 75M. Regarding current trading prices, PBH is priced at $74.65, while ZYXI trades at $2.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas ZYXI's P/E ratio is -10.33. In terms of profitability, PBH's ROE is +0.12%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, PBH is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check ZYXI's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, WGRX has a market cap of 63.2M. Regarding current trading prices, PBH is priced at $74.65, while WGRX trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas WGRX's P/E ratio is -1.14. In terms of profitability, PBH's ROE is +0.12%, compared to WGRX's ROE of -7.42%. Regarding short-term risk, PBH is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check WGRX's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, GEG has a market cap of 58.7M. Regarding current trading prices, PBH is priced at $74.65, while GEG trades at $2.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas GEG's P/E ratio is -42.00. In terms of profitability, PBH's ROE is +0.12%, compared to GEG's ROE of -0.02%. Regarding short-term risk, PBH is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check GEG's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, PBH is priced at $74.65, while HX trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas HX's P/E ratio is -1.84. In terms of profitability, PBH's ROE is +0.12%, compared to HX's ROE of -0.13%. Regarding short-term risk, PBH is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check HX's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, RDGT has a market cap of 7.3M. Regarding current trading prices, PBH is priced at $74.65, while RDGT trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas RDGT's P/E ratio is -0.38. In terms of profitability, PBH's ROE is +0.12%, compared to RDGT's ROE of -0.20%. Regarding short-term risk, PBH is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for PBH.Check RDGT's competition here

PBH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PBH stands at 3.7B. In comparison, CVET has a market cap of 0. Regarding current trading prices, PBH is priced at $74.65, while CVET trades at $20.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PBH currently has a P/E ratio of 17.40, whereas CVET's P/E ratio is -69.97. In terms of profitability, PBH's ROE is +0.12%, compared to CVET's ROE of -0.06%. Regarding short-term risk, PBH is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for PBH.Check CVET's competition here